Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Safety

Drug and asset intelligence for Safety with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
6
Catalysts
0
Stage
Development stage unavailable

Sponsor company

DHDDS-CDG →

Recent signals(6)

ClinicalAugust 9, 2026

Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali Initiated

A clinical trial is underway to evaluate the safety of the PfSPZ malaria vaccine in pregnant women in Mali.

ClinicalAugust 2, 2026

Safety and Feasibility Study of CD34+ Stem Cells in RUNX1 Familial Platelet Disorder

A study is underway to assess the safety and feasibility of mobilizing and collecting autologous CD34+ hematopoietic stem cells in patients with RUNX1 familial platelet disorder.

ClinicalAugust 1, 2026

Safety and Tolerability Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus

A study is underway to evaluate the long-term safety and tolerability of dapirolizumab pegol in patients with systemic lupus erythematosus.

ClinicalJuly 28, 2026

Safety and Effectiveness Study of IGBalloon for Obesity Treatment Initiated

A prospective study is underway to assess the safety and effectiveness of the IGBalloon in treating obesity with 20 participants.

ClinicalJuly 11, 2026

Safety Assessment of Propranolol for Infantile Hemangiomas Highlights Cardiovascular Risks

Real-world assessment of propranolol treatment for infantile hemangiomas indicates potential cardiovascular side effects.

ClinicalJune 23, 2026

Safety and Tolerability Study of NMN in DHDDS-CDG Patients Initiated

A clinical trial has been initiated to assess the safety and tolerability of NMN in patients with DHDDS-CDG.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

Congenital Disorders of Glycosylation →
Genetic Disorders →
Infectious Disease →
Obesity →
RUNX1 Familial Platelet Disorder →

Therapeutic areas

Congenital Disorders of Glycosylation →
Dermatology →
Device →
Genetic Disorders →
Hematology →
Immunology →
Infantile Hemangiomas →
Infectious Disease →
Malaria →
Obesity →
RUNX1 Familial Platelet Disorder →
Systemic Lupus Erythematosus →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.